comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-01 17:19:58 - browse：5

President Joe Biden talks in the Roosevelt Room of the White House, in front of a painting of Theodore Roosevelt on a horse back — politics coverage from STAT — President Biden MANDEL NGAN/AFP via Getty Images

WASHINGTON — The White House is throwing its support behind a controversial authority that allows the government to undermine patent rights for certain high-priced medicines. It’s an early step that could have major ramifications for the American pharmaceutical industry, depending on whether and how federal officials actually use the authority.

The administration issued a framework for the National Institutes of Health to more broadly use so-called “march-in rights” — a policy that allows it to invalidate patent rights from drugmakers whose products rely on federally funded research. The framework lays out when the agency might assert this authority, and endorse using a drug’s price in that determination.

“We’ll make clear that when drug companies won’t sell taxpayer funded drugs at reasonable prices, we will be prepared to allow other companies to provide those drugs for less,” White House National Economic Advisor Lael Brainard told reporters. “These authorities are in existing laws, the last administration just didn’t want to allow them to be used in this way.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： HHS secretary Becerra pressed on Change HealthCare cyberattack

WSS

President Biden's budget: Here's what you might have missed

Change Healthcare outage fallout shows need for new oversight

Mirador, a new biotech startup, launches with $400 million

UCLA team creates talking throat patch for voice disorders

Medicare Advantage insurers pressure Biden for bigger payments

Readout Newsletter: Bristol, Sangamo, Gilead, and more

leisure time

comprehensive

explore

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

United colonoscopy coverage change 'may cost lives,' doctors say

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Anesthesiologist group: stop taking Ozempic before surgery

Change Healthcare outage fallout shows need for new oversight

BioMarin wins approval for gene therapy to treat hemophilia A

Pregnancy ages women, but effects reverse after delivery

Cancer drug shortages should be causing more outrage

Why scientists need input from humanists on sensitive research

entertainment

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

U.K. officials, researchers try to ease path for bespoke genetic treatments

Readout Newsletter: CAR

Biotech investment managers search for lucrative opportunities

John Green on his newest strategy for fighting tuberculosis

Ebola: Gilead Sciences antiviral shows promise as new treatment

entertainment

hotspot

leisure time

focus